Needham maintains Evolent Health at Buy, raises price target to $6 from $5

Needham kept its Buy rating on Evolent Health and raised its price target to $6 from $5, a 20% increase. The new target suggests a 32.2% upside from the Nov 5 close of $4.54, according to the firm.

Original reporting
Published Nov 5, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Needham maintains Evolent Health at Buy, raises price target to $6 from $5 — source image
Decision brief

The 30-second read

$EVHBullishMed
01

Why it matters

The upgrade may attract short-term buying, but lacks supporting earnings or guidance details.

02

Market read

Analyst price target increase could drive modest buying pressure in EVH.

03

What to watch

No new fundamental data released; price target may reflect optimism rather than concrete results.

Relevance 6/10Novelty 6/10Timing: today

Background

Needham's rating upgrade is the primary news item; no other company data is provided.

Company-level read

Ticker impact

$EVHBullishMedium confidence
Context

Needham raised its price target on Evolent Health to $6 from $5, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new target implies a 32% upside from the current price, prompting buying interest.

Market effects

May lift sentiment in the healthcare services sector.

Limited to US-listed healthcare stocks.

Low

Counterpoint

Target raise could be premature if earnings miss expectations.

Key entities

  • Evolent Health

    Provider of healthcare technology and services.

  • Needham

    Investment research firm issuing the rating.

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.